Quarterly report pursuant to Section 13 or 15(d)

Organization and Nature of Operations (Tables)

v3.22.2.2
Organization and Nature of Operations (Tables)
9 Months Ended
Sep. 30, 2022
Basis of Presentation and Going Concern Condition [Abstract]  
Schedule of company's subsidiaries consolidated financial statements
Name of Subsidiary   Place and date of Incorporation   Percentage of Ownership   Principal Activities

Avalon Healthcare System, Inc.
(“AHS”)

 

Delaware

May 18, 2015

  100% held by ALBT   Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (“USA”)
             

Avalon (BVI) Ltd.

(“Avalon BVI”)

 

British Virgin Island

January 23, 2017

  100% held by ALBT  

Dormant,

is in process of being dissolved

             

Avalon RT 9 Properties LLC

(“Avalon RT 9”)

 

New Jersey

February 7, 2017

  100% held by ALBT   Owns and operates an income-producing real property and holds and manages the corporate headquarters
             

Avalon (Shanghai) Healthcare Technology Co., Ltd.
(“Avalon Shanghai”)

 

PRC

April 29, 2016

  100% held by AHS   Ceased operations
             

Genexosome Technologies Inc.

(“Genexosome”)

 

Nevada

July 31, 2017

  60% held by ALBT   Dormant
             

Avactis Biosciences Inc.

(“Avactis”)

 

Nevada

July 18, 2018

  60% held by ALBT   Integrate and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers
             

Avactis Nanjing Biosciences Ltd.

(“Avactis Nanjing”)

 

PRC

May 8, 2020

 

100% held by

Avactis

  Owns a patent
             

International Exosome Association LLC

(“Exosome”)

 

Delaware

June 13, 2019

  100% held by ALBT   Promotes standardization related to exosome industry